175 related articles for article (PubMed ID: 21317957)
1. Predictors of physical activity and quality of life in New Zealand prostate cancer survivors undergoing androgen-deprivation therapy.
Keogh JW; Shepherd D; Krägeloh CU; Ryan C; Masters J; Shepherd G; MacLeod R
N Z Med J; 2010 Nov; 123(1325):20-9. PubMed ID: 21317957
[TBL] [Abstract][Full Text] [Related]
2. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer.
Joly F; Alibhai SM; Galica J; Park A; Yi QL; Wagner L; Tannock IF
J Urol; 2006 Dec; 176(6 Pt 1):2443-7. PubMed ID: 17085125
[TBL] [Abstract][Full Text] [Related]
3. Perceptions of physically active men with prostate cancer on the role of physical activity in maintaining their quality of life: possible influence of androgen deprivation therapy.
Keogh JW; Patel A; MacLeod RD; Masters J
Psychooncology; 2013 Dec; 22(12):2869-75. PubMed ID: 23904113
[TBL] [Abstract][Full Text] [Related]
4. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review.
Bylow K; Mohile SG; Stadler WM; Dale W
Cancer; 2007 Dec; 110(12):2604-13. PubMed ID: 17960609
[TBL] [Abstract][Full Text] [Related]
5. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
6. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
7. Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer.
Alibhai SM; Breunis H; Timilshina N; Johnston C; Tomlinson G; Tannock I; Krahn M; Fleshner NE; Warde P; Canning SD; Klotz L; Naglie G
J Clin Oncol; 2010 Dec; 28(34):5038-45. PubMed ID: 21041715
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
[TBL] [Abstract][Full Text] [Related]
9. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer.
Mottet N; Prayer-Galetti T; Hammerer P; Kattan MW; Tunn U
BJU Int; 2006 Jul; 98(1):20-7. PubMed ID: 16566812
[TBL] [Abstract][Full Text] [Related]
10. Body image and quality of life in men with prostate cancer.
Harrington JM; Badger TA
Cancer Nurs; 2009; 32(2):E1-7. PubMed ID: 19258822
[TBL] [Abstract][Full Text] [Related]
11. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy.
Herr HW; O'Sullivan M
J Urol; 2000 Jun; 163(6):1743-6. PubMed ID: 10799173
[TBL] [Abstract][Full Text] [Related]
12. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
[TBL] [Abstract][Full Text] [Related]
13. Fatigue in prostate cancer survivors treated with definitive radiotherapy and LHRH analogs.
Kyrdalen AE; Dahl AA; Hernes E; Hem E; Fosså SD
Prostate; 2010 Sep; 70(13):1480-9. PubMed ID: 20687221
[TBL] [Abstract][Full Text] [Related]
14. Comparing eccentric resistance exercise in prostate cancer survivors on and off hormone therapy: a pilot study.
Hansen PA; Dechet CB; Porucznik CA; LaStayo PC
PM R; 2009 Nov; 1(11):1019-24. PubMed ID: 19942188
[TBL] [Abstract][Full Text] [Related]
15. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era.
Gjertson CK; Asher KP; Sclar JD; Goluboff ET; Olsson CA; Benson MC; McKiernan JM
Urology; 2007 Oct; 70(4):723-7. PubMed ID: 17991544
[TBL] [Abstract][Full Text] [Related]
16. Information needs of men on androgen deprivation therapy.
Soeyonggo T; Warde P; Fleshner N; Timilshina N; Alibhai SM
BJU Int; 2012 May; 109(10):1503-9. PubMed ID: 21883845
[TBL] [Abstract][Full Text] [Related]
17. Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients.
Moyad MA
Urol Oncol; 2005; 23(1):56-64. PubMed ID: 15885584
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
19. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation.
Mohile SG; Bylow K; Dale W; Dignam J; Martin K; Petrylak DP; Stadler WM; Rodin M
Cancer; 2007 Feb; 109(4):802-10. PubMed ID: 17219443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
